Pfizer held nine percent of the world's pharmaceutical drug market in 2022. The global market for prescribed medicines is expected to be led by U.S. companies, accompanied by Swiss pharma giants Roche and Novartis. Prescription and over-the-counter drugsThe total global prescription drug market – including generic and orphan drugs – was estimated at 1.12 trillion U.S. dollars for 2022. Especially the orphan drug market is a major driver and expected to more than double its revenues in only seven years between 2019 and 2026. Prescribed (Rx) drugs are drugs which can be only obtained with a physician’s prescription. In contrast to these, there is the group of so called over-the-counter (OTC) drugs which can be purchased directly without a prescription. Typical examples for OTC drugs are lower-dosed pain killers like aspirin or ibuprofen. Pfizer as global leaderNew York City-based Pfizer has been among the largest pharmaceutical companies for many years based on combined prescribed and OTC drug revenue. Today, the company is totally focused on human medicine, divided into four major segments: Primary Care, Specialty Care, Oncology, and Pfizer Centreone. Pfizer also had a significant animal health division until 2013. The company generates about half of its revenues inside the United States. Among Pfizer’s perhaps most famous drug ever produced is the potency pill Viagra.

In 2025, the company reported basic net earnings per common share of 1.37 U.S. dollars. Pfizer generated a net income of about eight billion U.S. dollars in the same period. The impact of rising costs on earnings per share The net income of Pfizer dramatically increased around fourfold between 2023 and 2024, evident in the company’s net earnings per share, which increased by over one U.S. dollar. Rising research and development costs can be a contributing factor in the decrease in net income. In relation to revenues, the pharmaceutical industry is one of the biggest investors in research and development. Revenues increased due to the COVID-19 vaccine Thanks to record-breaking sales of the COVID-19 vaccine Comirnaty, Pfizer generated its highest total revenues in the years 2021 and 2022. In general, the majority of Pfizer’s revenues comes from the manufacture and sale of its products, and revenues from the company’s domestic market of the United States account for a share of around 60 percent. Pfizer sells its pharmaceutical products in more than 125 countries worldwide, with the United States, China, and Japan being its three largest markets.

The U.S. Pharmaceutical Market size was valued at USD 4.1 billion in 2023 and is projected to reach USD 5.96 billion by 2032, exhibiting a CAGR of 5.48 % during the forecasts period. Recent developments include: In December 2023, Pfizer received all regulatory approvals for the acquisition of Seagen. This initiative aims to bring commercial changes in the organization thereby creating a new space, the Pfizer Oncology Division to integrate oncology commercial and R&D operations from both the companies. , In January 2023, Sun Pharma announced the launch of a new drug, SEZABY for treating neonatal seizures in the U.S. This is the first USFDA-approved drug for term and pre-term babies. .

Pfizer generated a net income of over eight billion U.S. dollars in 2024. The company reported basic net earnings per common share of 1.42 U.S. dollars. The impact of rising costs on earnings per share The net income of Pfizer dramatically increased around fourfold between 2023 and 2024, evident in the company’s net earnings per share, which increased by over one U.S. dollar. Rising research and development costs can be a contributing factor in the decrease in the net income. In relation to revenues, the pharmaceutical industry is one of the biggest investors in research and development. Revenues increased due to COVID-19 vaccine Thanks to record-breaking sales of COVID-19 vaccine Comirnaty, Pfizer generated its highest total revenues in the years 2021 and 2022. In general, the majority of Pfizer’s revenues comes from the manufacture and sale of its products, and revenues from the company’s domestic market of the United States accounts for a share of around 60 percent. Pfizer sells its pharmaceutical products in more than 125 countries worldwide, with the United States, China, and Japan being its three largest markets.

The COVID-19 vaccine market analysis reveals a -37.4% CAGR decline, shifting from pandemic-driven surges to a smaller, more stable market. Explore key trends, leading companies like Pfizer & Moderna, and regional market share insights for 2025-2033.

Sales from the United States contributed more than 37 billion U.S. dollars. Pfizer's total revenue was around 63 billion U.S. dollars in 2025. Pfizer sees strong growth in emerging markets Pfizer’s total revenue is divided into four geographic areas: the United States, Developed Markets, and Emerging Markets. China is one of the company’s largest single markets behind the United States, which contributed 60 percent of Pfizer’s total revenue. Pfizer continues to support investment in emerging markets, but the vulnerable nature of these countries means strategies come with an element of risk due to unforeseen financial or political events, for example. The power of product patents Managing the expiration of key patents is one of the greatest challenges facing Pfizer because competition from generic versions can make a big difference to the company's revenues. Many of Pfizer’s leading products enjoy the security of market exclusivity, but less expensive generic versions are free to enter the market when these property rights end. In 2019, Pfizer anticipated a fall in sales revenue from China due to significant competition from generic versions.

Discover the explosive growth potential of the global Pharmerging market. This comprehensive analysis reveals key drivers, trends, and restraints shaping the future of pharmaceutical innovation in emerging economies, including market size projections, regional breakdowns, and top industry players. Learn how rising healthcare expenditure, increasing prevalence of chronic diseases, and technological advancements are driving this dynamic sector.

Pfizer reported $155.55B in Market Capitalization this March of 2026, considering the latest stock price and the number of outstanding shares.Data for Pfizer | PFE - Market Capitalization including historical, tables and charts were last updated by Trading Economics this last March in 2026.

Discover the latest insights into the booming global pharmaceutical market. Explore market size projections, CAGR analysis, key drivers, and emerging trends influencing brand and generic drug sales through 2033. Learn about leading players like Pfizer, Roche, and J&J, and regional market dynamics in North America, Europe, and Asia-Pacific.

Revenues generated from outside the United States accounted for almost ********** of Pfizer's total revenue in 2025. During that year, the company generated revenues of roughly ** billion U.S. dollars in the United States. China emerges as an important market Pfizer sells its pharmaceutical products in more than *** countries worldwide, with the United States, China, and Japan being among the major national markets. In 2024, the United States alone contributed a share of more than ** percent. In terms of geographic area, emerging markets – which include China – generated revenues of approximately *** billion U.S. dollars in 2024. Analyzing Pfizer’s global operations In 2024, Pfizer had approximately 81,000 employees worldwide. The American company had ** manufacturing sites in countries ranging from Belgium to Singapore, each producing products that serviced the company’s commercial division. Pfizer also had several facilities that focused on research and development projects, many of which were located in North America.

Pfizer stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news.

The Women's Disease Pharmaceutical Market is booming, projected to reach $150 billion by 2025 with a 5% CAGR. Discover key trends, market segments (heart disease, cancer, gynecological health), leading companies, and regional insights in this comprehensive analysis.

Discover the latest market analysis of Tozinameran, the mRNA COVID-19 vaccine. Explore key growth drivers, market size projections (2025-2033), leading companies (Pfizer, BioNTech, Takeda), and regional market shares. Understand the impact of ongoing booster programs and emerging variants on future market trends.

The specialty pharmaceuticals market is booming, projected to reach $XX million by 2033 with a 35.40% CAGR. Discover key drivers, trends, and regional insights impacting this rapidly growing sector dominated by leading players like AbbVie, Johnson & Johnson, and Pfizer. Explore market segmentation by therapeutic area, route of administration, and distribution channels. Recent developments include: In March 2022, Intellia Therapeutics, Inc. received US Food and Drug Administration (FDA) orphan drug designation for Intellia's ex vivo investigational T cell receptor (TCR)-T cell therapy, NTLA-5001, for the treatment of acute myeloid leukemia (AML)., In February 2022, Optum launched Optum Specialty Fusion, a specialty medication management solution, to simplify care for patients with complex conditions and lower the cost of expensive specialty drugs.. Key drivers for this market are: Increasing Burden of Chronic and Rare Diseases, Growing Research and Development Activities. Potential restraints include: Increasing Burden of Chronic and Rare Diseases, Growing Research and Development Activities. Notable trends are: Oncology Segment is Expected to Account for the Large Market Share Over the Forecast Period.

The global generic drugs market is booming, projected to reach [estimated 2033 market size in billions] by 2033. Driven by rising healthcare costs and patent expiries, this comprehensive market analysis explores key trends, segments (oral, injection), leading companies (Teva, Novartis, Pfizer), and regional growth opportunities. Discover the future of affordable healthcare.

The global specialty pharmaceutical market is booming, projected to hit $850 billion by 2025, driven by chronic disease prevalence and biotech innovation. Explore market trends, CAGR, leading companies (Pfizer, Roche, Amgen), and regional insights in our comprehensive analysis.

The JAK Inhibitor-Based Cancer Drug market is booming, projected to reach $1.8 billion by 2033 with a 5.7% CAGR. Learn about market drivers, trends, restraints, and key players like Pfizer and Incyte in this comprehensive analysis. Discover regional market shares and future growth projections.

Discover the latest market analysis on Hay-well Syndrome Treatment, projecting a $236.7 million market value in 2025 and a 3.8% CAGR. Explore key drivers, trends, and restraints impacting growth, along with leading companies and regional insights. Learn about innovative treatment approaches and future market prospects.

The Pneumococcal Vaccines Market is estimated to be valued at USD 9.6 billion in 2025 and is projected to reach USD 14.4 billion by 2035, registering a compound annual growth rate (CAGR) of 4.1% over the forecast period.

Discover the booming Meropenem Powder market: Explore key trends, growth drivers, and competitive landscape insights from 2019-2033. This analysis reveals market size, CAGR, and regional market share, featuring major players like Pfizer and Sandoz. Learn how increasing antibiotic resistance and healthcare spending fuel market expansion.